Redeye notes that Sedana Medical’s Q4 report showed higher sales than our estimates, though EBITDA was fairly in line with our expectations. We believe Sedana Medical stands a chance to make a considerable return to growth during 2024, which could better point to its likelihood of success in the future US launch.
LÄS MER